AMBS as it stands will not be uplisting, especially with how the stock has tanked recently. There will have to be some sort of financial engineering, as Gerald likes to say, to get it uplisted. And even that might not work, hence why the company is in talks with NASDAQ to figure out how to do so within its guidelines. In the mean time, I wait patiently to hear news of the first patient enrolled in the ESS-W trial.